Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT long-term antibody persistence and 10-year booster study
2012-005639-10Phase 3
- Sponsor
- GSK
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine and meningococcal ACYW135 vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoints: Long-term antibody persistence and Booster immunogenicity.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccinemeningococcal ACYW135 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-005639-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005639-10.